Richard Ghalie
Chief Tech/Sci/R&D Officer bei MEI PHARMA, INC.
Vermögen: 5 784 $ am 31.03.2024
Profil
Richard G.
Ghalie currently works at Viracta Subsidiary, Inc., as Director from 2015 and MEI Pharma, Inc., as Chief Medical Officer from 2021.
Dr. Ghalie also formerly worked at Immunex Corp., as Senior Medical Director-Oncology Products from 1994 to 2001, Rush University Medical Center, as Medical Director-Bone Marrow Transplant Center, Poniard Pharmaceuticals, Inc., as VP-Clinical Research & Regulatory Affairs from 2001 to 2003, Ligand Pharmaceuticals, Inc., as VP-Medical Affairs & Professional Services from 2003 to 2007, Favrille, Inc., as Chief Medical Officer from 2007 to 2009, Novalar Pharmaceuticals, Inc., as Chief Medical Officer, HemaQuest Pharmaceuticals, Inc., as Chief Medical Officer, and Denovo Biopharma LLC, as Chief Medical Officer.
Dr. Ghalie received his Masters Business Admin degree from the University of Washington, doctorate degree from St. Joseph's College, and graduate degree from Université Paris Diderot-Paris 7.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
MEI PHARMA, INC.
0,02% | 30.10.2023 | 1 446 ( 0,02% ) | 5 784 $ | 31.03.2024 |
Aktive Positionen von Richard Ghalie
| Unternehmen | Position | Beginn |
|---|---|---|
| MEI PHARMA, INC. | Chief Tech/Sci/R&D Officer | 01.03.2016 |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Director/Board Member | 01.06.2015 |
Ehemalige bekannte Positionen von Richard Ghalie
| Unternehmen | Position | Ende |
|---|---|---|
| Favrille, Inc. | Chief Tech/Sci/R&D Officer | 22.04.2009 |
| LIGAND PHARMACEUTICALS INCORPORATED | Chief Tech/Sci/R&D Officer | 01.01.2007 |
| PONIARD PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01.01.2003 |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Corporate Officer/Principal | 01.01.2001 |
Denovo Biopharma LLC
 Denovo Biopharma LLC Pharmaceuticals: MajorHealth Technology Denovo Biopharma LLC provides a novel biomarker solution to personalize drug development. It applies in oncology, metabolic, cardiology, immunology and neurology therapeutic areas. The company is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Richard Ghalie
| University of Washington | Masters Business Admin |
| St. Joseph's College | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| PONIARD PHARMACEUTICALS, INC. | Health Technology |
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| MEI PHARMA, INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
| Favrille, Inc. | Health Technology |
Novalar Pharmaceuticals, Inc.
 Novalar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Novalar Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It focuses on dental products. The company's OraVerse product (phentolamine mesylate) reverses the effects of local anesthetic with a vasoconstrictor and accelerates the return of normal sensation and function. The company was founded in 2000 and is headquartered in San Diego, CA. | Health Technology |
| Université Paris Diderot-Paris 7 | Consumer Services |
Rush University Medical Center
 Rush University Medical Center Medical/Nursing ServicesHealth Services Rush University Medical Center engages in the provision of health care services. The company was founded in 1972 and is headquartered in Chicago, IL. | Health Services |
HemaQuest Pharmaceuticals, Inc.
 HemaQuest Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology HemaQuest Pharmaceuticals, Inc. develops small molecule therapeutics. Its products include hydroxyurea, a therapeutic agent for the treatment of underlying pathology of sickle cell anemia and for the treatments of beta thalassemia, sickle cell anemia, neutropenia, and various hematological disorders. The company was founded by Ronald J. Berenson, Douglas V. Faller, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos and Robert Williams in October 2007 and is headquartered in San Diego, CA. | Health Technology |
Denovo Biopharma LLC
Denovo Biopharma LLC Pharmaceuticals: MajorHealth Technology Denovo Biopharma LLC provides a novel biomarker solution to personalize drug development. It applies in oncology, metabolic, cardiology, immunology and neurology therapeutic areas. The company is headquartered in San Diego, CA. | Health Technology |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Health Technology |
